Changes in Antibody Seroprevalence of Seven High-Risk HPV Types between Nationwide Surveillance Studies from 1995-96 and 2006-07 in The Netherlands

PLoS ONE

Volumn 7, Issue 11, 2012, Pages

  Scherpenisse, Mirte ^a,b   Mollers, Madelief ^a,b   Schepp, Rutger M ^a   Boot, Hein J ^a   Meijer, Chris J L M ^b   Berbers, Guy A M ^a   van der Klis, Fiona R M ^a   de Melker, Hester E ^a  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS ANTIBODY; WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ANTIBODY SPECIFICITY; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHILD; CROSS-SECTIONAL STUDY; DEMOGRAPHY; DYNAMICS; ETHNIC DIFFERENCE; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; IMMUNOASSAY; IMMUNOSURVEILLANCE; INFANT; INFECTION RATE; MAJOR CLINICAL STUDY; MALE; MARRIAGE; MULTIPLEX IMMUNOASSAY; NETHERLANDS; NEWBORN; PAPILLOMAVIRUS INFECTION; POPULATION RESEARCH; PRESCHOOL CHILD; SCHOOL CHILD; SEROPREVALENCE; SEXUAL BEHAVIOR; SEXUALLY TRANSMITTED DISEASE; TREND STUDY; URBANIZATION; VACCINATION; VIRUS LIKE AGENT; WART VIRUS;

ADOLESCENT; ADULT; AGED; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; FEMALE; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; NETHERLANDS; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; POPULATION SURVEILLANCE; RISK FACTORS; SEROEPIDEMIOLOGIC STUDIES; SEROTYPING; YOUNG ADULT;

HUMAN PAPILLOMAVIRUS;

EID: 84869057659     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0048807     Document Type: Article

References (41)

1. Woodman CB, Collins SI, Young LS, (2007) The natural history of cervical HPV infection: unresolved issues. Nat Rev Cancer 7: 11-22.
2. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, et al. (1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 189: 12-19.
3. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM, (2011) Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: Variation by geographical region, histological type and year of publication. Int J Cancer 128: 927-935.
4. Markowitz LE, Sternberg M, Dunne EF, McQuillan G, Unger ER, (2009) Seroprevalence of human papillomavirus types 6, 11, 16, and 18 in the United States: National Health and Nutrition Examination Survey 2003-2004. J Infect Dis 200: 1059-1067.
5. Newall AT, Brotherton JM, Quinn HE, McIntyre PB, Backhouse J, et al. (2008) Population seroprevalence of human papillomavirus types 6, 11, 16, and 18 in men, women, and children in Australia. Clin Infect Dis 46: 1647-1655.
6. Heiligenberg M, Michael KM, Kramer MA, Pawlita M, Prins M, et al. (2010) Seroprevalence and determinants of eight high-risk human papillomavirus types in homosexual men, heterosexual men, and women: a population-based study in Amsterdam. Sex Transm Dis 37: 672-680.
7. Stone KM, Karem KL, Sternberg MR, McQuillan GM, Poon AD, et al. (2002) Seroprevalence of human papillomavirus type 16 infection in the United States. J Infect Dis 186: 1396-1402.
8. Carter JJ, Koutsky LA, Hughes JP, Lee SK, Kuypers J, et al. (2000) Comparison of human papillomavirus types 16, 18, and 6 capsid antibody responses following incident infection. J Infect Dis 181: 1911-1919.
9. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD, (1998) Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med 338: 423-428.
10. Einstein MH, Schiller JT, Viscidi RP, Strickler HD, Coursaget P, et al. (2009) Clinician's guide to human papillomavirus immunology: knowns and unknowns. Lancet Infect Dis 9: 347-356.
11. Stanley M, (2010) HPV: immune response to infection and vaccination. Infect Agent Cancer 5: 19.
12. af Geijersstam V, Kibur M, Wang Z, Koskela P, Pukkala E, et al. (1998) Stability over time of serum antibody levels to human papillomavirus type 16. J Infect Dis 177: 1710-1714.
13. Antonsson A, Green AC, Mallitt KA, O'Rourke PK, Pandeya N, et al. (2010) Prevalence and stability of antibodies to 37 human papillomavirus types-a population-based longitudinal study. Virology 407: 26-32.
14. Armstrong BK, Allen OV, Brennan BA, Fruzynski IA, de Klerk NH, et al. (1986) Time trends in prevalence of cervical cytological abnormality in women attending a sexually transmitted diseases clinic and their relationship to trends in sexual activity and specific infections. Br J Cancer 54: 669-675.
15. Dal Bello B, Spinillo A, Alberizzi P, Cesari S, Gardella B, et al. (2009) Time trends of human papillomavirus type distribution in Italian women with cervical intraepithelial neoplasia (CIN). Gynecol Oncol 115: 262-266.
16. Hemminki K, Li X, Vaittinen P, (2002) Time trends in the incidence of cervical and other genital squamous cell carcinomas and adenocarcinomas in Sweden, 1958-1996. Eur J Obstet Gynecol Reprod Biol 101: 64-69.
17. Ivansson EL, Gustavsson IM, Wilander E, Magnusson PK, Gyllensten UB, (2009) Temporal trends over 3 decades and intrafamilial clustering of HPV types in Swedish patients with cervical cancer in situ. Int J Cancer 125: 2930-2935.
18. De Melker HE, Conyn-van Spaendonck MA, (1998) Immunosurveillance and the evaluation of national immunization programmes: a population-based approach. Epidemiol Infect 121: 637-643.
19. van der Klis FR, Mollema L, Berbers GA, de Melker HE, Coutinho RA, (2009) Second national serum bank for population-based seroprevalence studies in the Netherlands. Neth J Med 67: 301-308.
20. Scherpenisse M, Mollers M, Schepp RM, Boot HJ, de Melker HE, et al. (2012) Seroprevalence of seven high-risk HPV types in The Netherlands. Vaccine.
21. Austin PC, (2010) Absolute risk reductions, relative risks, relative risk reductions, and numbers needed to treat can be obtained from a logistic regression model. J Clin Epidemiol 63: 2-6.
22. Dillner J, (2000) Trends over time in the incidence of cervical neoplasia in comparison to trends over time in human papillomavirus infection. J Clin Virol 19: 7-23.
23. Kibur M, af Geijerstamm V, Pukkala E, Koskela P, Luostarinen T, et al. (2000) Attack rates of human papillomavirus type 16 and cervical neoplasia in primiparous women and field trial designs for HPV16 vaccination. Sex Transm Infect 76: 13-17.
24. Laukkanen P, Koskela P, Pukkala E, Dillner J, Laara E, et al. (2003) Time trends in incidence and prevalence of human papillomavirus type 6, 11 and 16 infections in Finland. J Gen Virol 84: 2105-2109.
25. Anttila A, Pukkala E, Soderman B, Kallio M, Nieminen P, et al. (1999) Effect of organised screening on cervical cancer incidence and mortality in Finland, 1963-1995: recent increase in cervical cancer incidence. Int J Cancer 83: 59-65.
26. Nielsen A, Munk C, Kjaer SK, (2011) Trends in incidence of anal cancer and high-grade anal intraepithelial neoplasia in Denmark, 1978-2008. Int J Cancer.
27. Siebers AG, Klinkhamer PJ, Grefte JM, Massuger LF, Vedder JE, et al. (2009) Comparison of liquid-based cytology with conventional cytology for detection of cervical cancer precursors: a randomized controlled trial. Jama 302: 1757-1764.
28. (2011) Landelijke Evaluatie Bevolkingsonderzoek naar Baarmoederhalskanker (LEBA) rapportage 2011.
29. van Veen MG, Kramer MA, Op de Coul EL, van Leeuwen AP, de Zwart O, et al. (2009) Disassortative sexual mixing among migrant populations in The Netherlands: a potential for HIV/STI transmission? AIDS Care 21: 683-691.
30. Brugman E, Goedhart H, Vogels T, Zessen G van (1995) Jeugd en seks 95: resultaten van het nationale scholierenonderzoek. Oudenoord: NISO.
31. Graaf Hd, Meijer S, Poelman J, Vanwesenbeeck I (2005) Seks onder je 25e. Seksuele gezondheid van jongeren in Nederland anno 2005. Oudenoord: NISO.
32. Kramer M, Mollema L, Smits G, Boot H, de Melker H, et al. (2010) Age-specific HPV seroprevalence among young females in The Netherlands. Sex Transm Infect 86: 494-499.
33. Rama CH, Villa LL, Pagliusi S, Andreoli MA, Costa MC, et al. (2010) Seroprevalence of human papillomavirus 6, 11, 16, and 18 in young primiparous women in Sao Paulo, Brazil. Int J Gynecol Cancer 20: 1405-1410.
34. Syrjanen S, (2010) Current concepts on human papillomavirus infections in children. Apmis 118: 494-509.
35. Lindau ST, Schumm LP, Laumann EO, Levinson W, O'Muircheartaigh CA, et al. (2007) A study of sexuality and health among older adults in the United States. N Engl J Med 357: 762-774.
36. Jena AB, Goldman DP, Kamdar A, Lakdawalla DN, Lu Y, (2010) Sexually transmitted diseases among users of erectile dysfunction drugs: analysis of claims data. Ann Intern Med 153: 1-7.
37. Poulos CA, Sheridan DJ, (2008) Genital injuries in postmenopausal women after sexual assault. J Elder Abuse Negl 20: 323-335.
38. Bodley-Tickell AT, Olowokure B, Bhaduri S, White DJ, Ward D, et al. (2008) Trends in sexually transmitted infections (other than HIV) in older people: analysis of data from an enhanced surveillance system. Sex Transm Infect 84: 312-317.
39. Castle PE, Schiffman M, Herrero R, Hildesheim A, Rodriguez AC, et al. (2005) A prospective study of age trends in cervical human papillomavirus acquisition and persistence in Guanacaste, Costa Rica. J Infect Dis 191: 1808-1816.
40. Lazcano-Ponce E, Herrero R, Munoz N, Cruz A, Shah KV, et al. (2001) Epidemiology of HPV infection among Mexican women with normal cervical cytology. Int J Cancer 91: 412-420.
41. Vaccarella S, Franceschi S, Clifford GM, Touze A, Hsu CC, et al. (2010) Seroprevalence of antibodies against human papillomavirus (HPV) types 16 and 18 in four continents: the International Agency for Research on Cancer HPV Prevalence Surveys. Cancer Epidemiol Biomarkers Prev 19: 2379-2388.